IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

An Overview Of Implantable Drug Delivery System For The Management Of Diabetic Mellitus

Abhijit K. Banait[1], Abhishek R. Kale[2], Aditi D. Jamankar[3], Achyut R. Kandalkar[4]

Yashkumar A. Meshram[5]

Jagadambha Institute Of Pharmacy & Research, Kalamb, Maharastra 445401, India

Abstract :

Implantable medicine delivery systems(IDDSs) are a promising result for precise and safe medicine delivery. They can reduce systemic toxin and deliver remedial loads directly to target apkins, thereby avoiding multiple transport walls and unwanted side goods. IDDSs have been successfully applied in clinical settings, and their use is anticipated to grow in the coming times. Implantable medicine delivery systems offer controlled medicine release at the specific point of implantation, minimizing side goods and adding patient compliance. The periodic expenditure of treating diabetes exceeds$ 1 trillion encyclopedically and$ 327 billion in the United States alone. Although there have been some developments in the treatment of diabetes, similar as the use of Advances In Diabetes Care Including Insulin Pumps, the technology used to manage diabetes has substantially stayed same over the times. The implantable drug delivery bias, similar as an insulin pump, can be integrated with these wearable glucose detectors. The study of presently accessible implantable medicine delivery systems is the main focal point on this review. Also focus on evaluation parameter of implant, system of implant manufacture, bracket of implantable polymeric medicine delivery device system, unborn aspects of IDDS. The remedial operations Of IDDS, Ideal parcels of implantable medicine delivery systems, implantable insulin delivery technologies for diabetes operation(Advances In Diabetes Care Including Insulin Pumps), also bandied to motivate unborn technological development toward bettered patient care in diabetes operation.

Keywords : Implantable drug delivery, implants, Implantable pump, Insulin pump, Diabetes management.

1. Introduction.

Implantable medicine delivery systems are placed entirely under the skin generally in a applicable but normal position. The case is alive of only a small bump under the skin. designed to transfer of medicines and fluids into the bloodstream without the replicate insertion of needles. well suited to the medicine delivery necessity of insulin, steroids, chemotherapeutics, antibiotics, anesthetics, total parenteral nutrition, and heparin there's little possibility of infection or intervention with diurnal conditioning Because the device is fully subcutaneous, with no opening in the skin.[1] What's Implantable medicine delivery systems.



Fig. 1:Implantable drug delivery systems[2]

Implantable bias have capability to minimise the need of frequent medicine input as well as authorize drug requirements with approachable way. At present, these bias are generally employed in numerous remedial areas similar as contraception, chemotherapy, dentistry etc. The expanding product and request bareness of implants are apparent of immense growth in this sector.

Analysis began, within the late- 1930s by Danckwerts, on sustained release implantable medicine delivery systems operate by hypodermic route. This discovery sparked AN interest within the space of implants develop in further studies and also the demand for implantable systems can increase Bastille Day sire, through 1998, to$5.9 billion annually.[3] The late 1800s and early 1900s are appertained to as the" medicine revolution" period for medicine discovery. During this time, a number of the recently discovered medicine products were developed and employed to treat colorful ails, either as maquillages or liquids administered orally or topically. Small changes were made. considered regarding lozenge forms, medicine delivery systems, tube medicine situations, IV operation, or their applicability in medicine result until the early tomid-1900s.

The demand for parenteral and implanted structures is prognosticated to increase by 14 time over time. over till 1998, to$ 59 billion each time. Because the device will be implanted, biocompatibility with the mortal terrain is pivotal. There are conditions that must be met for a substance to be biocompatible. implanted pumps that store medicines and medicine implants have historically been classified as the two most significant classes for labelling implanted medicine shipping systems. The first and foremost fineness controls the kinetics of how snappily drug is released from the shipping device by utilizing colorful types of polymers and polymeric membranes. analogous divisions of the biodegradable and nonbiodegradable structures that make up this first organisation of implants are possible. Research started out, with in side the history due- Nineteen Thirties through Danckwerts, on sustained launch implantable medicine shipping Administered through subcutaneous direction.

This discovery sparked hobbyhorse with in side the position of implants main to also exploration and the call for implantable structures will boom 14 in keeping with time, via 1998, to$5.9 billion annuall[4]. IDDS represents a smart interface between the natural target and the medicine depot. Importantly for the nonsupervisory purposes, IDDSs are combination products that combine two or further regulated factors similar as medicines, medical bias, or natural products that serve as a single reality[5,6].

Diabetes is an incorrigible habitual complaint performing from a insufficiency in the product(Type I) or the resistance of insulin(Type II), which has come a leading cause of mortal deaths worldwide, counting for ≈11.3 according to the International Diabetes Federation[7]. The quality of life for people with diabetes is significantly affected by habitual hyperglycemia and glucose toxin, which may also lead to serious microvascular and macrovascular com plications similar as cardiovascular complaint, blindness, neuropathy, and nephropathy[8].

Presently, the most effective defense against the progression of diabetes is to develop a substantiated operation plan via frequent monitoring and evaluation of glucose situations throughout the day(i.e., at least four times a day and twice a day for type I and type II diabetes, independently). This enables diabetic cases to acclimate applicable mealtime insulin dosing, thereby reducing the threat of complications.[9] Presently, alongside cardiovascular complaint and cancer, diabetes mellitus has surfaced as a type of majornon-communicable complaint with a high death and morbidity rate.

Inadequate insulin product and insulin resistance are the main symptoms of diabetes mellitus and are brought on by inheritable, environmental, microbial, vulnerable system, and internal factors. According to the norms of the World Health Organization(WHO), diabetes mellitus is classified into type 1 diabetes mellitus(T1DM), type 2 diabetes mellitus(T2DM), gravid diabetes, and special types of diabetes. In China, cases with T2DM account for the maturity of all cases, about 90%[10].

2. Ideal properties of IDDS.

- Reduce the frequency of drug administration during the whole course of treatment to increase patient compliance.
- The medicine is released in a rate-controlled manner, increasing its effectiveness and reducing its side effect.Simple to manufacture and comparatively cheap.[11]
- Easy to sterilize.
- Rate controlled release of drug.
- Easy to manufacture and relatively inexpensive.
- Good mechanical strength.
- Free from surgical procedure.[12]
- The implant needs to have adequate mechanical strength and be secure, stable, and functional.

3. Advantages of the IDDS.



Fig. 2: Illustrates the advantages of an implantable drug delivery system.[13]

4. Disadvantages of the IDDS.

- Large- sized implants bear surgery, which is a painful process.
- Remedy can not be simply discontinued[15].
- The response between host and implant[16].

The disadvantages of Implantable medicine delivery include similar factors as.

4.1. Invasive.

Either a minor or a significant surgery is demanded to initiate medical care. The needs the respectable surgical labor force, and should be traumatic, long. Beget some scar conformation at the positioning of implantation and terribly veritably bitsy portion of case could lead to surgery- related complication[11]. To initiate remedy either a minor or a major surgical procedure is needed to initiate remedy. Applicable surgical labor force are needed for this, and may be time consuming traumatic[14]. The case has to face either a major or a minor surgical procedure[16].

4.2. Termination.

Non-biodegradable chemical emulsion implants and prolixity pumps indeed be surgically recaptured at the tip of treatment. Though a perishable chemical emulsion implant doesn't need surgical reclamation. Its uninterrupted biodegradation makes it tough to terminate medicine delivery. Or to take care of the right will at the tip of its lifetime[3]. Non-biodegradable polymeric implants after reduction of medicine, they need to be removed by surgical system[16].

4.3. Danger of device failure.

There's no associated peril with this treatment that the device may for some reason fail to work. This again requires surgical involvement to correct[14].

4.4. Limited to potent drugs.

Associate in nursing implants are frequently veritably little. so as to lessen the discomfort of the case. Since utmost systems only have a small lading capacity, only extremely strong specifics, similar hormones, are used. Conceivably suitable for distribution using implanted technology.

4.5. Possibility of adverse responses.

The point of implantation receives a high attention of the medicine delivered by Associate in Nursing implant. This native high medicine attention could spark adverse responses[3].

4.6. Biocompatibility issues.

Biocompatibility and implant safety enterprises are constantly aggravated by worries about how the body may reply to a foreign material. .

4.7. Marketable disadvantages.

The creation of an IDDS requires a significant quantum of time, plutocrat, and trouble in R&D. still, its comity must be completely assessed in order to win the blessing of controlling authorities, If a new material is proposed to be used in the creation of an implant. These issues are a result of critical development creation detainment.

5. Medicine release depends upon.

- Via the polymer, medicine prolixity
- Nonbiodegradable polymers, similar as polymethylsone, are utilised to produce lozenge forms.
- The medicine's dissolution.
- Utilized for biodegradable polymers like polyglycolic acid and polylactic acid, among others.

6. Limitation of the IDDS.

- Possible toxin & price of ingrained new implant[14].
- Need for microsurgery to implant the system.
- Possible pain.
- Difficulty in shutting off release if necessary[5].

7. Drug Used For The Implantable Drug Delivery System.

Table 1: Drugs used for the implantable drug delivery systems.

Drug Used For The Implantable Drug Delivery System	
Name Of Drug	**Purpose**
Progestin+Estradiol, Megestrol, Norgestrel	Contraception
Ibuprofen, Naproxen, Phenylbutazone	Polyarthritis
Cyclophosphamide, Merchloroethamide	Cancer
Piocarpine	Glaucoma
Morphine	Narcotic addiction studies

8. Classification of IDDS With Their Diagrammatically Representation Of Mechanism Of Drug Release From Of Implantable Polymeric Drug Delivery Device:



Fig. 3: A broad classification of active and passive implantable drug delivery systems.

9. Evaluation Parameter Of Implant.

In the evaluation of implants after fabrication using any suitable approach, various parameters are executed. These include the following,

9.1. Shape and size.

Vernier Callipers are used in convergence with light to confirm an implant's size.

9.2. Livery viscosity.

The individual viscosity of separate implants as well as the variations among them is determined by using Vernier Calipers. At least three samples must be determined and average value is set up out[17,18].

9.3. Uniform Weight.

The end of this test is to calculate the steady weight of each implant. The test is performed by arbitrary selection of twenty implants and importing them singly. Mean weight is attained. From the results, two implants must not weigh further than the mean weight and none of them must have twofold value of mean[19].

9.4. Shelf Life and Stability.

Implants are tested for their shelf life and stability under various storage conditions to determine their expiry date and storage recommendations.

10. System Of Implant Manufacture.

10.1. Extrusion system.

Firstly named drug is dissolved in a suitable soap system to produce a result. After that polymer is added into the result slowly and allowed to stand for 10- 15 beats for soaking purposes. The bloated material developed had been blended slightly till it forms a dough- suchlike material. The dough was transferred into the extruder cylinder and had been extruded in the form of long rods by the help dis . Implants dried the whole night at room temperature, and also cut into the optimum size and dried at 40oC[20].

10.2. Compression Method.

To produce the result, the polymer and medicine were dissolved. To produce a homogeneous croquette, the created result was snap- dried. The croquette was compressed in order for the implant to develop. Implants were created using a Carver hydraulic press at a pressure of 1 metric tonne and a pristine brand system designed specifically for this purpose, which included a set of 1 mm fringe globular punches.

10.3. Putrefying system.

Result of polymer and the drug was firstly prepared in a suitable soap system and also vanquished for the lyophilization and converted to a steady croquette after that before the set croquette was putrefied into rods through a Teflon distance toast on a hot plate at a temperature about 100- 120oC[21].

11. Remedial operations Of IDDS.

Generally, IDDS involving the following important operations analogous as

- Women’s health
- Diabetes
- Cancer
- In Tuberculosis
- Immunization
- optic remedy
- Cardiovascular system
- Pain operation.

- **Women's health.**

Women's health is one area where implantable drug delivery bias have had associate out sized impact, especially in their use for contraception. In 1990, Norplant came the first implantable contraception device to be approved. Implantable long recreation contraceptives ar shown to be the among the foremost effective nicely contraception, with Associate in Nursing periodic maternity rate of still 1 Chronicles for women victimization these ways that[37] shows samples of implantable drug delivery bias to be employed in women's health.

- **Diabetes.**

Diabetes is a habitual complaint sate where implantable systems have the eventuality to transform the current standard of both opinion and treatment.

- **Cancer.**

The major challenge in anticancer remedy is to develop IDDS's to deliver chemotherapeutic drugs safety and effectively with out side effects. Ex. Zoladex.

- **In Tuberculosis.**

The fundamental problems in the treatment of TB long duration of remedy and side goods of drugs. Which can hamper patient life and induce patient non- compliance, treatment failure, and development of drug resistant strains.

- **Optic use.**

Membrane controlled bias, silicone bias, infusion bias and different implantable bias are popularly used to deliver drugs for prolonged optic use. Ocusert is a classic illustration of membrane controlled device containing a pilocarpin with alginate inside medicine reserve enclosed with ethylene vinyl acetate membrane. This device provides outburst of drug firstly also follows zero order release profile of drug at 20-40 milligrams hourly for diurnal period. It extends good operation of intraocular pressure(IOP) with insignificant adverse issues and is well accepted in grown- ups whereas deficiently permitted in elderly people[38].

- Social unit of medical aid agents is that the most common route of administration. still, it generally involves delivery of the agents at their most permitted cure which can beget severe side- goods like blood complaint and cardiomyopathy.

- Associate in Nursing implantable drug delivery device would be ideal to produce positive case compliance and completion of the treatment. Poor case compliance to anodyne treatment could also be a typical frequence and causes a high trouble of relapse, treatment and completely different negative issues[39].

- Roaring treatment of optic conditions conjurations that the cure of drug or remedial agent is delivered to the placement of action and saved for the amount that the treatment is demanded. this could be especially worrisome among the attention due to poor drug achromatism and poor drug retention among the attention thanks to tearing, tear dilution and incision development.

- Implantable drug delivery bias overcome variety of those challenges to delivery by reducing the number of treatment operations demanded, but in addition accompany their own challenges including burst unleash, the probability of cure commerce, and low bioavailability[40].

12. Advances In Diabetes Care (Insulin Pump).

12.1. Current Technologies for Diabetes Treatment.

For cases with type I diabetes and more advanced type II diabetes that can not maintain normoglycemia vianon-insulin specifics and life change, injection or infusion of insulin is demanded. Buried from pancreatic?- cells, endogenous insulin is a protein hormone that's able of regulating the blood glucose attention within the range of 80 – 130 mg · dL −1. Being unable of generating endogenous insulin, cases with diabetes need exogenous insulin, similar as beast insulin, recombinant mortal insulin, or insulin analogs[23,24].

For cases with late- stage diabetes with serious complications, pancreas or island transplantation may be their only option. still, due to deficit of whole organ pancreas, cadaveric β- cells islands, as well as

xenogeneic islands deduced from mortal embryonic stem cells, convinced pluripotent stem cell, and β- cells-unoriginal genetically finagled cells, are being laboriously delved[24].

12.2. Insulin Pumps.

Insulin pumps are medical bias that give insulin to diabetics on a nonstop base from a force. There are three types of insulin pumps in general they're as given below.

a. Conventional insulin pumps.
b. Patch insulin pumps.
c. Implantable insulin pumps.

a. Conventional insulin pumps.

The traditional insulin pump includes a wearable main body, tubing, and an infusion cannula(Fig. 5). The main body houses an insulin force, a pump medium, a power source, as well as necessary control, communication, and programming circuits to acclimate insulin infusion rate. An infusion cannula is implanted subcutaneously with the divisible needle[28].

b. Patch insulin pumps.

Patch pumps as well as durable pumps are anticipated to directly deliver programmed rudimentary rates and insulin boluses to insure a safe remedy and achieve acceptable glycemic control. In this disquisition, insulin delivery delicacy of the new patch pump was assessed and compared to another patch pump and a durable pump previous to its global request preface. All factors of the pump, including the pump body, tubing, cannula and cartridge, are combined to a single unit, which can be stuck directly to the stoner's skin.

This insulin patch pump can be removed before bathing to avoid dropped energy of insulin due to thermal denaturation. The disposable corridor of the pump (cannula and cartridge) are consumable inventories while the driving part(pump body) is applicable(Fig. 6)[26]

a. Conventional insulin pumps.



Fig. 4: Components of an insulin pump.

b. Patch insulin pumps.



Fig. 5: component of pump system : pump control (above).[26]

c. Implantable insulin pumps.



Fig. 6: The MiniMed Medtronic model 2007 intraperiteneal insulin pumps.[27]

c. Implantable insulin pumps.

Implantable insulin pumps (IIPs) have the advantage of being less visible and have a lower effect on everyday life conditioning. Above all, treatment by programmable IIPs should be more physiologic for two reasons. First, intraperitoneal insulin infusion offers a more physiologic route of insulin delivery and thus a better pharmacodynamic profile. With intraperitoneal administration, the insulin is absorbed into the portal rotation, 50 of the cure being uprooted by the first liver pass and also distributed to systemic blood[29]. Fast immersion from the peritoneum, together with a pattern of high portal insulin attention and lower insulin attention, is performing in more rapid-fire action (insulin peaks at 70vs. 120 min subcutaneously) and rapid-fire concurrence of insulin (165 min, as with normal subjects). therefore, the threat of hypoglycemia compared with subcutaneous injection is reduced[30].

12.3. Challenges Associated with Insulin Pumps.

One of the nuisances of the wearable insulin pump is that the subcutaneously implanted cannula needs to be replaced at least formerly every week[31]. There are also pitfalls of kinking or bending the cannula due to migration and movement of the external factors. utmost significantly, implicit infection and occlusion due to the foreign body response can beget a severe problem for the case. colorful approaches have been developed to extend the continuance and ameliorate the bio-compatibility of the implants. Chug. reported that the material for the infusion cannula can be modified to release nitric oxide, which improves bio-compatibility by precluding platelet activation and adhesion[32].

Their S nitroso- N- acetylpenicillamine saturated coating released NO for further than 14 days, and remained stable for 30 days. In addition to new accoutrements , face structures can also be used to help face fouling and foreign body response. In the work by Xu , oxygen tube was used to etch polytetrafluoroethylene(PTFE) shells to form nanopillar structures[33]. These nanostructured shells have been demonstrated to have bactericidal and anti-inflammatory parcels. Several other approaches have been developed to ameliorate the biocompatibility of the implants, including hydrophilic accoutrements , biomimetic, zwitter ionic, and other smart polymer accoutrements[34,35,36].

13. Conclusion and Future Prospects.

The innovative approach of implantable medicine delivery systems for controlled medicine release at remedial situations. It highlights their advantages over traditional administration styles and emphasizes ongoing exploration to ameliorate biodegradability,bio-compatibility, and reduce immunogenicity and toxin of the accoutrements used. These systems hold the eventuality to offer extended, harmonious medicine release biographies, reducing the need for frequent dosing, enhancing cost- effectiveness, medicine efficacy, and patient compliance. They're particularly precious for administering newer, protein- grounded medicines that can not be taken orally, addressing failings of former medicine delivery systems. In this review, we

epitomized the recent development of new seeing and treatment styles for diabetes care. In particular, we stressed the arising trends of wearable glucose detectors and their seeing modalities.

In the section on implantable medicine delivery, we epitomized presently available treatment plans for diabetes cases. The choice of insulin pump type depends on individual preferences, life, and medical requirements. Conventional pumps give dependable control, while patch pumps offer convenience and discretion. Implantable pumps, with their physiological advantages, may be a suitable option for those seeking a more natural insulin delivery system. The selection of the right insulin pump should be made in discussion with healthcare professionals to insure effective diabetes operation and bettered glycemic control.

Reference.

1. Hussain, Soeb & Solanki, Dharmendra & Yadav, Rajat & Khan, Yusuf. (2021). Implantable Drug Delivery System: An Overview.

2. Ramesh, K., Gupta, S., Ahmed, S., & Kakkar, V. (2017). A Comprehensive Study on Design Trends and Future Scope of Implantable Drug Delivery Systems.

3. Ms. Aishwarya Sandip Ankaram, Ms Shubhangi Raosaheb Mali, June 2022, Implantable Polymeric Drug Delivery Devices: Classification, Manufacture and Clinical Applications: International Journal of Research Publication and Reviews, Vol 3, no 6, pp 3200-3205.

4. Rajgor N, Patel M1, Bhaskar VH, July-December 2011, Implantable Drug Delivery Systems: An Overview: Vol 2 | Issue

5. Choi, S.H.; Wang, Y.; Conti, D.S.; Raney, S.G.; Delvadia, R.; Leboeuf, A.A.; Witzmann, K. Generic drug device combination products: Regulatory and scientific considerations. Int. J. Pharm. 2018, 544, 443–454.

6. Al-Jawadi, S.; Capasso, P.; Sharma, M. The road to market implantable drug delivery systems: A review on US DA's regulatory framework and quality control requirements. Pharm. Dev. Technol. 2018, 23, 953–963.

7. I. D. Federation, Diabetes increases the risk of health complications, https://www.diabetesatlas.org/en/sections/individual-social-and economic-impact.html (accessed February 2021)

8. Donnelly, R., Emslie-Smith, A. M., Gardner, I. D., & Morris, A. D. (2000). Vascular complications of diabetes. *Bmj*, *320*(7241), 1062-1066.

9. Ahmadi, A., Kabiri, S., & Omidfar, K. (2020). Advances in HbA1c biosensor development based on field effect transistors: a review. *IEEE Sensors Journal*, *20*(16), 8912-8921.

10. Alberti, K. G., and Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of A WHO consultation. Diabet Med. 15, 539–553.doi:10.1002/(sici)10969136(199807)15:7<539::aid-dia668> 3.0.co;2-s

11. Ms. Aishwarya Sandip Ankaram, Ms Shubhangi Raosaheb Mali, June 2022, Implantable Polymeric Drug Delivery Devices: Classification, Manufacture and Clinical Applications: International Journal of Research Publication and Reviews, Vol 3, no 6, pp 3200-3205.

12. Dr.K. Jesindha Beyatricks, Mrs. Ashwini S. Joshi, October 2021, Implantable drug delivery systems: NIRALI PRAKASHAN ; ISBN 978-93- 90225-01-9.

13. Salave, S., Rana, D., Sharma, A., Bharathi, K., Gupta, R., Khode, S., ... & Kommineni, N. (2022). Polysaccharide based implantable drug delivery: Development strategies, regulatory requirements, and future perspectives. Polysaccharides, 3(3), 625-654.

14. Mohammad Zaki AJ., Satish K. Patil1, Dheeraj T. Baviskar1,Dinesh K. Jain, Jan-Mar 2012, Implantable Drug Delivery System: A Review; International Journal of PharmTech Research, Vol.4, No.1, pp 280-292.

15. Soeb Hussain, Dharmendra Solanki, Rajat Yadav, Yusuf Khan, March 2021 , Implantable Drug Delivery System: An Overview ;Vol.:20, Issue:4 : 116-132.

16. Gupta, M. B Pharm 7th Semester Novel Drug Delivery Systems BP-704T Unit-2 Implantable Drug Delivery Systems.

17. Patel S Taher, SenguptaMukul, Fast Dissolving Pill Technology – A Review. World Journal of Pharmacy and Pharmaceutical Sciences, 2013; 2(2):485-508.

18. Jameela SR, Kumary TV, Lal AV, Jayakrishnan A, Progesterone loadedchitosan microspheres: A long acting biodegradable controlled delivery system,J Control Release, 1998; 52(12):1724.https://pubmed.ncbi.nlm.nih.gov/9685932/https://doi.org/10.1016/S01683659(97)00187-9

19. Islam, S., Islam, S., & Urmi, A. B. (2012). Observation of the release of aspirin from gelatin-sodium alginate polymeric implant. *J Chem Pharm Res*, *4*(12), 5149-56.

20. - Aulton, M. E. (2002). Pharmaceutics: The science of dosage form design. *(No Title)*.

21. - Zhou Q, Armstrong B, Larson I, Stewart PJ, Morton DA. Improving powder flow properties of a cohesive lactose monohydrate powder by intensive mechanical dry coating. J Pharm Sci 2010;99:969-81.

22. Zhao, R., Lu, Z., Yang, J., Zhang, L., Li, Y., & Zhang, X. (2020). Drug delivery system in the treatment of diabetes mellitus. *Frontiers in bioengineering and biotechnology*, *8*, 880.

23. Tibaldi, J. M. (2014). Evolution of insulin: from human to analog. *The American journal of medicine*, *127*(10), S25-S38.

24. Q. Ge, L. Chen, K. Chen, J. Diabetes Res. 2017, 2017, 5837804. J. Li, J. Y. Liang, S. J. Laken, R. Langer, G. Traverso, Trends Chem. 2020, 2, 319.

25. A. J. Vegas, O. Veiseh, M. Gürtler, J. R. Millman, F. W. Pagliuca, A. R. Bader, J. C. Doloff, J. Li, M. Chen, K. Olejnik, Nat. Med. 2016, 22, 306.

26. 1.Baumstark A, Mende J, Uchiyama J, Haug C, Freckmann G. Description of a Novel Patch Pump for Insulin Delivery and Comparative Accuracy Evaluation. Journal of Diabetes Science and Technology. 2022;16(4):971-975.doi:10.1177/19322968211000441

27. Catargi, Bogdan. "Current status and future of implantable insulin pumps for the treatment of diabetes." Expert Review of Medical Devices, vol. 1, no. 2, 1 Nov. 2004, pp. 181+. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A265373797/HRCA?u=googlescholar&sid=bookmark-HRCA&xid=0a627887. Accessed 6 Sept. 2023.

28. Zhang, J., Xu, J., Lim, J., Nolan, J. K., Lee, H., & Lee, C. H. (2021). Wearable glucose monitoring and implantable drug delivery systems for diabetes management. *Advanced Healthcare Materials*, *10*(17), 2100194.

29. Selam JL, Raymond M, Jacquemin JL, Orsetti A, Richard JL, Mirouze J. Pharmacokinetics of insulin infused intraperitoneally via portable pumps. Diabetes Metab. 11, 170-173 (1985).

30. Nathan DM, Dunn FL, Bruch J et al. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. Am. J. Med. 100, 412-417 (1996).

31. Zhou, Y., Zhang, Q., Wu, J., Xi, C., & Meyerhoff, M. E. (2018). Synthesis and characterization of a fluorinated S-nitrosothiol as the nitric oxide donor for fluoropolymer-based biomedical device applications. *Journal of Materials Chemistry B*, *6*(38), 6142-6152.

32. Chug, M. K., Feit, C., & Brisbois, E. J. (2019). Increasing the lifetime of insulin cannula with antifouling and nitric oxide releasing properties. *ACS applied bio materials*, *2*(12), 5965-5975.

33. Xu, J., Moon, H., Xu, J., Lim, J., Fischer, T., McNally, H. A., ... & Lee, H. (2020). One-step large-scale nanotexturing of nonplanar PTFE surfaces to induce bactericidal and anti-inflammatory properties. *ACS applied materials & interfaces*, *12*(24), 26893-26904.

34. Xu, J., & Lee, H. (2020). Anti-biofouling strategies for long-term continuous use of implantable biosensors. *Chemosensors*, *8*(3), 66.

35. Xu, J., Xu, J., Moon, H., Sintim, H. O., & Lee, H. (2021). Zwitterionic liquid crystalline polythiophene as an antibiofouling biomaterial. *Journal of Materials Chemistry B*, *9*(2), 349-356.

36. Chen, X., & Yang, D. (2020). Functional zwitterionic biomaterials for administration of insulin. *Biomaterials Science*, *8*(18), 4906-4919.

37. Rademacher K.H., Vahdat H.L., Dorflinger L., Owen D.H., Steiner M.J. Critical Issues in Reproductive Health. Springer; Dordrecht, The Netherlands: 2014. Global Introduction of a Low-Cost Contraceptive Implant; pp. 285–306

38. Siepmann J, Siepmann F, Modeling of diffusion controlled drug delivery, Journal of Controlled Release, 2012; 161(2):351-62. https://doi.org/10.1016/j.jconrel.2011.10.006

39. De Souza R., Zahedi P., Allen C.J., Piquette-Miller M. Polymeric drug delivery systems for localized cancer chemotherapy. Drug Deliv. 2010;17:365–375. doi: 10.3109/10717541003762854.

40. Manickavasagam, D., & Oyewumi, M. O. (2013). Critical assessment of implantable drug delivery devices in glaucoma management. *Journal of drug delivery*, *2013*.